In the low MDS group, 15 (88%) of the RTR that developed NODAT required treatment with hypoglycemic agents or insulin and in the high MDS group, 5 (100%) of the RTR that developed NODAT required treatment with hypoglycemic agents or insulin. This evidence concerns the gene INS and myelodysplastic syndrome.